Contrast Imaging Guidance Outlines Labeling Change Requirements
This article was originally published in The Pink Sheet Daily
In all cases, safety and efficacy of new contrast imaging indications must be established using device and drug data from clinical trials.
You may also be interested in...
FDA's Office of Combination Products says it is getting back on track with new leadership in place after months of flux. Industry meanwhile is pushing the office to accelerate the release of rules and guidelines to help companies navigate the relatively new area of regulation
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.
ORA sets a 2012 priority of improving the efficiency of the recall process to help reach its overall enforcement and compliance goal of preventing public health emergencies.